(-0.88%) 4 967.23 points
(0.56%) 37 986 points
(-2.05%) 15 282 points
(0.62%) $83.24
(0.17%) $1.760
(0.36%) $2 406.70
(1.29%) $28.75
(-1.17%) $943.30
(-0.14%) $0.938
(-0.21%) $11.02
(0.56%) $0.808
(-0.95%) $93.01
Live Chart Being Loaded With Signals
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States...
Stats | |
---|---|
Today's Volume | 378 240 |
Average Volume | 324 472 |
Market Cap | 75.42M |
EPS | $0 ( 2024-03-13 ) |
Next earnings date | ( $-0.0700 ) 2024-05-09 |
Last Dividend | $0.0150 ( 2015-09-16 ) |
Next Dividend | $0 ( N/A ) |
P/E | 3.26 |
ATR14 | $0.00900 (0.64%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-01 | Keutzer Timothy | Buy | 239 731 | Common Stock |
2024-02-02 | Keutzer Timothy | Sell | 30 971 | Common Stock |
2024-02-02 | Mahadevia Ankit | Sell | 63 795 | Common Stock |
2024-02-01 | Joseph Tamara L | Buy | 239 731 | Common Stock |
2024-02-02 | Joseph Tamara L | Sell | 30 906 | Common Stock |
INSIDER POWER |
---|
58.53 |
Last 96 transactions |
Buy: 6 234 250 | Sell: 2 240 393 |
Volume Correlation
Spero Therapeutics Inc Correlation
10 Most Positive Correlations | |
---|---|
AKYA | 0.855 |
COLB | 0.855 |
CARE | 0.85 |
ARQT | 0.842 |
CBAN | 0.835 |
FSEA | 0.833 |
FBMS | 0.832 |
FRBA | 0.826 |
FBIZ | 0.825 |
BIRD | 0.823 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Spero Therapeutics Inc Correlation - Currency/Commodity
Spero Therapeutics Inc Financials
Annual | 2023 |
Revenue: | $96.74M |
Gross Profit: | $96.37M (99.62 %) |
EPS: | $0.430 |
Q4 | 2023 |
Revenue: | $71.83M |
Gross Profit: | $71.79M (99.95 %) |
EPS: | $0.970 |
Q3 | 2023 |
Revenue: | $25.47M |
Gross Profit: | $25.37M (99.58 %) |
EPS: | $-0.0608 |
Q2 | 2023 |
Revenue: | $788 000 |
Gross Profit: | $-8.72M (-1 106.85 %) |
EPS: | $-0.230 |
Financial Reports:
No articles found.
Spero Therapeutics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0100 | 2010-03-30 |
Last Dividend | $0.0150 | 2015-09-16 |
Next Dividend | $0 | N/A |
Payout Date | 2015-10-07 | |
Next Payout Date | N/A | |
# dividends | 23 | -- |
Total Paid Out | $0.285 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.92 | -- |
Div. Sustainability Score | 7.56 | |
Div.Growth Potential Score | 0.378 | |
Div. Directional Score | 3.97 | -- |
Year | Amount | Yield |
---|---|---|
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.240 | 1.500 | 5.19 | 7.79 | [0 - 0.5] |
returnOnAssetsTTM | 0.130 | 1.200 | 5.66 | 6.79 | [0 - 0.3] |
returnOnEquityTTM | 0.339 | 1.500 | 7.34 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.53 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.42 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.05 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0304 | -1.500 | 9.49 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -20.59 | 1.000 | -8.74 | -8.74 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.623 | 2.00 | -0.208 | -0.415 | [0 - 30] |
freeCashFlowPerShareTTM | -0.623 | 2.00 | -0.311 | -0.623 | [0 - 20] |
debtEquityRatioTTM | 0.0519 | -1.500 | 9.79 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.811 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.200 | 1.000 | 8.00 | 8.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -5.95 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.542 | 0.800 | 9.72 | 7.78 | [0.5 - 2] |
Total Score | 7.56 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 3.79 | 1.000 | 9.72 | 0 | [1 - 100] |
returnOnEquityTTM | 0.339 | 2.50 | 8.29 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.623 | 2.00 | -0.208 | -0.623 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.623 | 2.00 | -0.208 | -0.415 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0105 | 1.500 | -3.40 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.334 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | 0.378 |
Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators